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Th e overall goals of extensively characterizing cancer 
genomes are to refi ne current therapies through defi ning 
markers of therapeutic responsiveness or resistance, and 
to identify targets for the development of novel thera­
peutic strategies. Achieving these goals requires the inte­
gration of vast amounts of complex multidimensional 
genomic data with insights from other systems. A 
recently published study by Reimand and Bader provides 
a timely example of the importance of large­scale eff orts 
in cancer genomics, and the valuable insights that mining 
these datasets can yield [1]. While cohort­based cata­
loguing of genomic aberrations initially reveals candidate 
driver events in diff erent cancer types, this group and 
many others are also interrogating these data using 
innovative approaches to distinguish between driver and 
passenger mutations. In this study, cancer genome data 
from 800 patients across 8  cancer types made publicly 
available by the International Cancer Genome Consor­
tium (ICGC) [2], the Cancer Genome Atlas (TCGA) [3,4] 
and independent groups [5] were analyzed using methods 
specifi cally designed to enrich for cancer drivers.
As we understand more about cancer genomes, pro­
found complexity and heterogeneity are emerging [6]. 
Apart from mutations in a relative handful of cancer 
driver genes that occur in a signifi cant proportion of 
tumors, the number of uncommon and rare mutations is 
extremely high. Th is poses challenges for the diff eren­
tiation of drivers versus passengers, as most approaches 
focus on recurrently mutated genes, and less frequently 
mutated genes are probabilistically defi ned by compari­
son to the background mutation rate across the whole 
genome [7]. As a consequence, new approaches that 
increase confi dence in candidate driver prediction are 
required to generate hypotheses for further study.
Driver mutations in the cancer kinome
Reimand and Bader [1] focused their eff orts on kinase 
genes that regulate phosphorylation, and regions of the 
genome that encode phosphorylation sites in known 
substrates, together known as the kinome. Th ese classes 
of genes play important roles in growth, homeostasis and 
are often dysregulated in cancer. As such, they are attrac­
tive therapeutic targets and have in some instances 
resulted in the development of eff ective therapies (for 
example, Erlotinib® for the treatment of lung cancers that 
harbor EGFR mutations). Th e authors developed 
‘ActiveDriver’, a novel computational algorithm that calcu­
lates the signifi cance of non­synonymous single nucleo­
tide variations within phosphoregulatory sites based on 
the local (gene­wide), rather than genome­wide back­
ground mutation rate, which assumes all areas of the 
genome have equal probability of harboring mutations. 
Th is approach increases the sensitivity of detection of 
signifi cant events within a given region of the genome; in 
this case, the gene where the mutation of interest is 
located. ActiveDriver identifi ed well­known cancer genes 
and showed that mutations at some specifi c phospho­
regulatory sites within these were associated with 
diff erential patient survival. In addition, they identifi ed 
novel candidate driver genes with existing functional data 
suggesting a role in carcinogenesis: FLNB, which has a 
role in cytoskeleton organization; GRM1, which increases 
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PI3K activity; and POU2F1, a POU domain transcription 
factor that regulates cell cycle progression. As a con se­
quence, they conclude that ActiveDriver complements 
existing analysis tools.
Next, they performed network analysis and defined 
modules of kinases that were hierarchically organized, 
and found that certain networks were associated with 
differential survival in ovarian cancer. This has significant 
implications for therapeutic development, as defining key 
functional dependencies or ‘weak points’ in otherwise 
robustly deregulated mechanisms could uncover attrac­
tive therapeutic targets. They hypothesized that PRKCZ 
is one such master regulator of a frequently mutated 
phosphoregulatory network that contains well­known 
cancer genes such as PTEN, which is inactivated in many 
cancer types and functions as a tumor suppressor by 
negatively regulating Akt/PKB signaling. Although there 
are no drugs that directly target PRKCZ, multiple 
inhibitors of an immediately upstream kinase, PDPK1, 
are available.
Strategies for enriching cancer driver genes
In general, several approaches can assist in enriching for 
candidate driver genes (Table  1) [8], many of which are 
exploited by Reimand and Bader [1]. These include the 
following approaches described below.
Increasing sample size and/or focus on uniform clinically 
relevant groups to define low frequency recurrent events
Current activities in this area include pan­cancer 
analyses, which can examine single genes, networks and 
pathways. The ICGC/TCGA goal within the next few 
years is to generate comprehensive genomic data for in 
excess of 25,000 cancer genomes, and when combined 
with other efforts the number is projected to be even 
greater.
Investigating the known characteristics of cancer genes
Reimand and Bader [1] exploited this in several ways: 
(1) choosing to focus on mutations in phosphoregulatory 
sites, (2) validating ActiveDriver by detecting well­known 
cancer genes, and (3)  using insights from other studies. 
In addition, other characteristics such as recurrent 
inactivation of genes using different mechanisms (point 
mutation, deletion, methylation) in discovery efforts are 
supportive of a candidate tumor suppressor gene.
Pathway and network analysis
Numerous pathway analysis tools are available (for 
example, MsigDB, GeneGO and Reactome), and as the 
underlying information grows, hypotheses concerning 
function and mechanisms can be better developed.
Integrative analysis
Orthogonal global analysis using different methodologies 
can assist in enriching for candidate driver genes and 
pathways. These datasets can include other genomic 
analy ses; for example, transcriptome, epigenome or in­
cor porate model systems such as animal models (com­
parative genomics), or in vitro functional screens [9].
Identifying clinical correlates
Correlating with clinical parameters such as prognosis 
and therapeutic responsiveness can be supportive of 
func tional relevance of a mutated gene or pathway/
network. Further insights can be gained if there is asso­
ciation with distinct clinical features such as the pattern 
of disease spread, vascular invasion, lymph node 
Table 1. Outline of strategies that can be used to enrich for, identify and refine candidate driver genes and mechanisms in 
cancer: the underlying rationale, experimental approaches and computational tools 
Strategy Rationale Tools/data sources
Increasing sample size and clinical focus Decrease variability due to different disease states Statistical approaches; power calculations
Detect driver versus passenger events Determine significance of recurrent mutations after 
controlling for background mutation rate, gene size 
and regional complexity
MutSig; MuSIC; GISTIC2.0
Individual gene characteristics Computationally predict functional consequences ActiveDriver; CHASM; Polyphen2; SIFT; Mutationtaster
Integrative analysis and known 
characteristics of cancer drivers
Genomic characteristics of defined drivers inform 
functionally relevant events
Aligning genomic datasets (SNV, CNV, SV, methylation)
Pathway and network analysis Heterogeneity of individual genetic aberrations 
contributing to common mechanisms
MsigDB; GeneGO; Reactome; PINA; PARADIGM
Integrative multidimensional data analysis Orthogonal readouts of disease using different 
experimental approaches and model systems 
GEMM; chemically induced models; mutagenesis 
screens; shRNA screens
Clinical correlation Association with clinical characteristics may inform 
functional roles
Statistical methods
CNV, copy number variation; GEMM, Genetically Modified Mouse Model; shRNA, short hairpin RNA; SNV, single nucleotide variation; SV, structural variation.
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metastasis and perineural invasion. Reimand and Bader 
identify associations with survival for both specific single 
gene events and networks [1].
Summary
Reimand and Bader [1] used large datasets for the 
purpose they were created; they developed a novel 
approach to address current challenges in analyzing 
genomes and used multiple methods to provide signifi­
cant insights into the molecular pathology of cancer. 
These data provide increased confidence in pursuing 
these target mechanisms through more detailed experi­
men tation. We are only at the beginning of mapping out 
the genomic events that exist in cancer, and the data 
analyzed in this report examined somatic single nucleo­
tide variants in the protein coding regions of genes [10]. 
Other classes of pathogenic mutation such as insertions, 
deletions, and translocations can dramatically impact 
gene function and also warrant investigation. Further­
more, other levels of gene regulation such as epigenetic 
modification and RNA­mediated events can be inte­
grated into these studies over time. As the cancer genome 
atlases continue to grow, it is anticipated the approach 
described in the Reimand and Bader study will lead to 
further significant insights into the underlying mecha­
nisms that play key roles in cancer. This is vitally 
important for more timely advances in intervention 
strate gies for cancer prevention, early detection and 
treatment.
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